Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Michigan PA/Step Therapy …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Formulary prior authorization and step therapy list (selected products)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists medications on the BCBSM Core Comprehensive Formulary 2026 (Medicare Plus Blue PPO) that require prior authorization (PA) or step therapy (ST), with brief coverage requirements and prerequisite therapy notes affecting prescribers and pharmacy benefit administrators.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyFormulary prior authorization and step therapy list (selected products)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document required prior therapy trials or diagnostic evidence per product-specific criteria before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Manyproducts listed with PA/ST requirements in this extract
    1 YEARmost common coverage duration specified
    Prerequisite therapyrequires prior Part D therapy (some products)
    Combination excludedexplicit combination exclusions for some biologics
    Indication-specificexamples: indication‑specific prerequisite/combos

    Coverage Criteria (Product-specific)

    Adbry: Initial and reauthorization criteria

    Covered when ALL of the following are met:

    Adbry initial coverage: Patient is at least 12 years of age AND has a diagnosis of moderate to severe atopic dermatitis AND has trialed and failed one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.age >= 12 years

    Reauthorization requires documentation of positive clinical response; dosage limits for patients <100 kg after 16 weeks (300 mg q4w) unless clinical rationale provided.

    Prolastin-c: Coverage criteria

    Covered when ALL of the following are met:

    Prolastin-c coverage: Patient has diagnosis of congenital alpha‑1 antitrypsin deficiency with symptomatic emphysema or necrotizing panniculitis AND documentation consistent with specified phenotypes (e.g., PIZZ, PIZ (NULL), or PI (NULL, NULL)) AND FEV1 < 80% predicted AND age >= 18 years.
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyFormulary prior authorization and step therapy list (selected products)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document required prior therapy trials or diagnostic evidence per product-specific criteria before requesting coverage.
    SourceLink
    On This Page
    Coverage Criteria (Product-specific)Provider Actions, Documentation & Prior AuthorizationInitial Therapy Criteria & RequirementsReauthorization and Continuation CriteriaStep Therapy RequirementsKey Clinical Thresholds & Coding ValuesQuantity Limits & DurationSite of Care & Part B vs Part D DeterminationsBackgroundDefinitions
    FEV1 < 80% predicted

    Coverage duration 1 year.

    Braftovi: Indication-specific combination requirements

    Coverage varies by indication; combination use and prior-therapy conditions are required as follows:

    Braftovi coverage by indication: For unresectable/metastatic melanoma with BRAF V600E or V600K mutation: requires prior trial of vemurafenib + cobimetinib OR combination use with binimetinib (per indication). For initial treatment of metastatic colorectal cancer with BRAF V600E mutation: requires combination with cetuximab and fluorouracil‑based chemotherapy; for CRC after prior therapy: requires combination with cetuximab. For metastatic NSCLC with BRAF V600E mutation: requires combination with binimetinib.BRAF V600E or V600K mutation documented

    Coverage duration 1 year; prerequisite Part D therapy flag applies.

    Cabometyx: Indication-specific prior therapy

    Coverage is provided when the prior-therapy or combination requirements for the requested indication are met:

    Cabometyx coverage by indication: First‑line advanced renal cell carcinoma: requires combination use with nivolumab. Hepatocellular carcinoma (HCC): requires prior trial of sorafenib. Locally advanced or metastatic differentiated thyroid cancer (radioactive iodine–refractory or ineligible): requires trial of a VEGFR‑targeted therapy.specific prior therapies tried as noted

    Coverage duration one year; prerequisite Part D drug required where indicated.

    Auvelity: Step therapy requirement

    Covered when ALL of the following are met:

    Auvelity (MDD) step therapy: Diagnosis of major depressive disorder AND trial of bupropion AND trial of one other generic formulary antidepressant prior to Auvelity initiation.trial of 2 agents

    Coverage duration: lifetime.

    Examples: oncology product-specific requirements

    Examples of oncology product‑specific prior‑therapy or combination requirements include:

    Mantle cell lymphoma (MCL): Patient has received at least one prior therapy for MCL; previously untreated MCL in patients ineligible for autologous HSCT requires combination use with bendamustine plus rituximab.

    Applies to listed oncology products; coverage duration one year.

    Combination therapy exclusion

    Not covered in combination scenarios:

    Combination therapy exclusion: Use in combination with another biologic or targeted DMARD indicated for the same condition is not permitted.

    Stated for multiple biologic/targeted DMARD entries; reauthorization typically requires documentation of positive clinical response.

    Dalfampridine

    Covered when ALL of the following are met:

    Dalfampridine initiation and reauthorization: Submission of a baseline timed 25‑foot walk (T25FW) prior to initiation AND reauthorization requires documentation of stability or improvement on T25FW. Excluded if the patient is wheelchair‑bound or becomes wheelchair‑bound.T25FW documented

    Coverage duration 1 year.

    Dupixent and related biologics

    Dupixent and related biologics are covered when indication‑specific diagnostic and prior‑therapy conditions are met:

    Atopic dermatitis (AD): Diagnosis of moderate to severe AD (age thresholds per indication) AND trial and treatment failure of one of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil. Reauthorization requires documentation of positive clinical response.age and prior therapy per indication

    AD age thresholds vary by product; coverage duration 1 year.

    Eosinophilic asthma (EA): Diagnosis of EA with eosinophil count >=150 cells/μL at initiation AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus a trial of one additional controller (leukotriene modifier, LABA, or LAMA).eosinophils >=150 cells/μL

    Per product‑specific requirements; see COPD and other respiratory indications for alternate thresholds.

    COPD add‑on maintenance: Uncontrolled moderate‑to‑severe COPD with eosinophil >=300 cells/μL AND current therapy with LABA + LAMA + inhaled corticosteroid (unless contraindicated) AND intent to continue those agents.eosinophils >=300 cells/μL

    Coverage duration 1 year.

    Seizure and migraine products

    Initial authorization requires specified prior trials or inability to tolerate oral formulations:

    Epidiolex and related antiepileptics: For Lennox–Gastaut, Dravet, and TSC‑associated seizures: trial of two generic alternatives as specified per diagnosis (Dravet: two of valproic acid, clobazam, or topiramate).

    Coverage duration 1 year; prerequisite Part D therapy required.

    Topiramate oral solution / migraine prevention: For migraine prevention: trial of at least two generic alternatives for migraine prevention unless patient cannot swallow tablets/capsules; for seizure disorder: trial of at least two generic anticonvulsants or inability to swallow tablets/capsules.

    Coverage duration 1 year.

    Product-level coverage criteria (selected excerpts)

    General product‑level rules and representative examples:

    General product-level conditions: Coverage is limited to medically‑accepted indications unless additional indication‑specific criteria are listed; many products have a coverage duration of 1 year (some LIFETIME); some products are subject to Part B vs Part D review.

    See individual product entries for precise requirements.

    Examples of indication-specific required trials or conditions: Examples include: schizophrenia treatments require trial of two generic atypical antipsychotics; eosinophilic asthma eligibility requires eosinophil thresholds and prior controller failure; rheumatoid arthritis biologics require prerequisite DMARD trials; select oncology agents require prior systemic therapies or combination with specific agents.

    Representative examples summarized from multiple product entries.

    Explicit exclusions: Combination use with another biologic or targeted DMARD for the same condition is explicitly excluded for certain biologics; some agents are excluded if used solely for weight loss.

    Applies to multiple biologic entries.

    IVIG product criteria

    Covered when ALL of the following are met:

    IVIG product coverage: Patient is unable to swallow the tablet formulation OR is unable to achieve the prescribed dose with tablet formulation, and the IVIG product is otherwise indicated for the condition.

    IVIG products are subject to Part B vs Part D review; coverage duration 1 year.

    Inlyta criteria

    Covered when ALL of the following are met:

    Inlyta (axitinib) in advanced RCC: First‑line treatment of advanced renal cell carcinoma requires combination use with avelumab or pembrolizumab. For other RCC indications, prior trial of one systemic therapy may be required per product line.

    Coverage duration one year.

    Kevzara indication-specific criteria

    Covered when ALL of the following are met:

    Kevzara for rheumatoid arthritis: Diagnosis of moderately to severely active RA AND trial of two of the following: etanercept (Enbrel), adalimumab biosimilars, Rinvoq, Xeljanz/XR, or Orencia. Reauthorization requires documentation of positive clinical response; cannot be combined with another biologic/targeted DMARD for the same condition.

    Coverage duration one year.

    Kevzara for polymyalgia rheumatica (PMR): History of corticosteroid treatment >10 mg/day prednisone equivalent for >=8 weeks AND inadequate response or intolerance to corticosteroids as demonstrated by disease flare during taper at >7.5 mg/day prednisone equivalent.

    Liraglutide coverage criteria

    Covered when ALL of the following are met:

    Liraglutide for T2DM: Either medical records confirming diagnosis of type 2 diabetes mellitus OR laboratory evidence (A1c >= 6.5% OR fasting plasma glucose >= 126 mg/dL OR 2‑hour plasma glucose >= 200 mg/dL).A1c >=6.5%; FPG >=126 mg/dL; 2‑hr PG >=200 mg/dL

    Excluded if used for weight loss only; coverage duration 1 year.

    Lonsurf coverage criteria

    Covered when ALL of the following are met:

    Lonsurf for metastatic colorectal cancer: Combination use with bevacizumab AND prior trial of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy AND an anti‑VEGF therapy. For RAS wild‑type mCRC, also requires prior anti‑EGFR therapy.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Post-transplant CMV prerequisite

    Covered when prerequisite therapies have been tried as required:

    Post‑transplant CMV prerequisite: Prior trial of one of ganciclovir, valganciclovir, cidofovir, or foscarnet is required for coverage of post‑transplant CMV infection/disease where listed.

    Referenced in products listing (e.g., Livtencity/Lonsurf context).

    Lonsurf metastatic CRC/gastric criteria

    Covered when ALL of the following are met:

    Lonsurf metastatic CRC/gastric criteria: Combination use with bevacizumab and prior trial of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and an anti‑VEGF therapy are required; for RAS wild‑type mCRC also requires trial of an anti‑EGFR therapy. Metastatic gastric/GEJ adenocarcinoma requires at least two prior lines of chemotherapy including specified agents.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Lumakras criteria

    Covered when ALL of the following are met:

    Lumakras for KRAS G12C NSCLC: KRAS G12C‑mutated locally advanced or metastatic NSCLC: requires trial of at least one prior systemic therapy. For KRAS G12C mCRC after prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, requires combination use with panitumumab.

    Coverage duration one year; prerequisite Part D therapy required.

    Lynparza multi-indication criteria

    Covered when ALL of the following are met (indication‑specific):

    Lynparza — ovarian/related cancers: Deleterious or suspected deleterious germline or somatic BRCA‑mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: requires trial of platinum‑based chemotherapy; some settings require combination with bevacizumab and prior platinum therapy.

    Coverage duration one year; prerequisite Part D therapy required.

    Lynparza — breast/pancreas/prostate indications: gBRCAm HER2‑negative metastatic breast cancer: requires prior chemotherapy in appropriate settings; HR‑positive breast cancer: requires prior endocrine therapy or documentation endocrine therapy is inappropriate; certain mCRPC HRR indications require prior enzalutamide or abiraterone; other tumor‑specific prior therapy rules apply.

    See product line for specific indication details.

    Mekinist indication-specific criteria

    Covered when ALL of the following are met:

    Mekinist indication-specific criteria: For BRAF‑mutant unresectable or metastatic melanoma (BRAF V600E or V600K) detected by an FDA‑approved test: monotherapy permitted for BRAF‑inhibitor treatment‑naive patients but many indications require trial of vemurafenib + cobimetinib or combination with dabrafenib per specific indication; liquid formulation coverage requires inability to swallow tablets and same mutation/combination requirements.BRAF V600E or V600K mutation detected by FDA‑approved test

    Coverage duration 1 year; prerequisite Part D therapy required.

    Mavyret guidance-aligned coverage

    Covered when consistent with specialty guidance:

    Mavyret (HCV): Criteria will be applied consistent with current AASLD/IDSA guidance for hepatitis C virus infection management.

    Coverage decisions follow up‑to‑date society guidance.

    Nexletol coverage criteria

    Covered when ALL of the following are met:

    Nexletol coverage: Diagnosis of hypercholesterolemia (including HeFH) or increased risk of major adverse cardiovascular events AND trial of one high‑intensity statin unless documented intolerance or contraindication; documentation of recent on‑treatment LDL while on high‑intensity statin may be required.LDL thresholds per product (see LDL guidance)

    Coverage duration 1 year.

    Movantik coverage criteria

    Covered when ALL of the following are met:

    Movantik initial criteria: Diagnosis of opioid‑induced chronic constipation in members with chronic, non‑cancer pain AND member is stable on opioid therapy for a minimum of 2 weeks prior to initiation. Initial coverage 3 months; renewal up to 1 year.

    Age restriction: 18 years and older.

    General product PA

    Covered when product‑specific prior authorization conditions are documented:

    General PA conditions: Prior authorization is required; coverage duration usually 1 year; product‑specific prerequisite therapy, diagnostic confirmation, or prescriber documentation must be provided as listed in individual product entries.

    See individual product lines for specific trials or diagnostic requirements.

    Nucala: indication-specific criteria

    Nucala coverage varies by indication and numeric thresholds:

    Nucala — eosinophilic asthma (EA): Diagnosis of EA with eosinophil count >=150 cells/μL at initiation AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus a trial of one additional controller (leukotriene modifier, LABA, or LAMA).eosinophils >=150 cells/μL

    Reauthorization requires documentation of positive clinical response.

    Nucala — EGPA: Diagnosis of EGPA with documentation of two typical EGPA clinical/pathologic criteria as listed in product entry.

    Per product entry; reauthorization requires positive clinical response.

    Nucala — HES: Diagnosis of hypereosinophilic syndrome (HES) with eosinophil count >=1000 cells/μL at initiation and stability on HES therapy.eosinophils >=1000 cells/μL
    Nucala — CRSwNP and COPD add‑on: CRSwNP: recurring polyps despite intranasal corticosteroids. COPD add‑on: uncontrolled moderate‑severe COPD with eosinophils >=150 cells/μL OR >=300 cells/μL within past 12 months AND current therapy with LABA + LAMA + inhaled corticosteroid unless contraindicated.eosinophil thresholds as above

    Coverage duration 1 year.

    Onureg: maintenance AML

    Covered when ALL of the following are met:

    Onureg maintenance in AML: Adult patient with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete count recovery (CRi) following intensive induction chemotherapy and who is not able to complete intensive curative therapy.

    Coverage duration 1 year.

    Opfolda: Pompe disease criteria

    Covered when ALL of the following are documented:

    Opfolda diagnostic and prior ERT requirement: Confirmation of decreased acid alpha‑glucosidase (GAA) activity on serum assay AND genetic testing demonstrating a GAA mutation AND presence of symptomatic manifestations (e.g., progressive muscle weakness, respiratory failure) AND lack of improvement on current enzyme replacement therapy (ERT).

    Coverage duration 1 year.

    Padcev: prior lines required

    Covered when ALL of the following are met:

    Padcev prior‑line requirement: Locally advanced or metastatic urothelial cancer: prior treatment with a PD‑1 or PD‑L1 inhibitor AND prior platinum‑containing chemotherapy OR ineligibility for cisplatin with at least one prior therapy line.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Combination therapy exclusion

    General rule applied to biologic/targeted DMARDs in this section:

    Combination therapy exclusion (general): Cannot be used in combination with another biologic or targeted DMARD indicated for the same condition.

    Applies across multiple biologic product entries.

    Polivy - Initial Therapy

    Initial therapy coverage when ALL of the following are met:

    Polivy initiation: Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), not otherwise specified: requires trial of at least two prior therapies.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Praluent - Indication-specific criteria

    Praluent initiation and specialty‑indication requirements:

    Praluent initiation LDL criteria: For ASCVD/primary hyperlipidemia/HeFH: documented LDL while on high‑intensity statin within last 120 days (>=55 mg/dL with ASCVD; >70 mg/dL without ASCVD) AND either continued statin on max tolerated dose or documented statin intolerance/contraindication.LDL thresholds per product

    Reauthorization requirements include continued LDL reduction; some HoFH and other criteria require genetic confirmation.

    Praluent — HoFH criteria: Genetic confirmation of homozygous familial hypercholesterolemia OR untreated LDL >500 (treated >300) with clinical features (early xanthoma or parental HeFH evidence); patient continues other lipid‑lowering therapy for reauthorization.

    Coverage duration for some indications may be 3 years per product entry.

    Eltrombopag - Indication-specific criteria

    Covered when the following baseline laboratory and prior‑therapy conditions are met:

    Eltrombopag — ITP: Persistent or chronic immune thrombocytopenia (ITP): baseline platelet count <30,000/mcL AND trial of corticosteroids, IVIG, or splenectomy as clinically appropriate.platelets <30,000/mcL

    Coverage duration 1 year.

    Eltrombopag — hepatitis C thrombocytopenia: Thrombocytopenia with chronic hepatitis C: baseline platelet count <75,000/mcL.platelets <75,000/mcL

    Rezdiffra - Initial and renewal

    Rezdiffra initial and renewal coverage requires ALL of the following:

    Rezdiffra initial coverage: Diagnosis of noncirrhotic NASH or MASH AND presence of advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive assessment AND trial of semaglutide prior to Rezdiffra initiation.F2–F3 fibrosis

    Coverage duration 1 year; prerequisite Part D therapy required.

    Rezdiffra renewal criteria: Patient has not progressed to cirrhosis AND at least one of: NASH/MASH resolution without fibrosis worsening, >=1‑stage fibrosis improvement without NASH worsening, or imaging/blood‑based evidence of improvement or stabilization.no progression to cirrhosis; fibrosis improvement or clinical benefit

    Reauthorization contingent on documented benefit.

    Retevmo - Tumor-specific criteria

    Covered when tumor‑specific molecular testing and prior‑therapy conditions are met:

    Retevmo — NSCLC with RET fusion: Adult patients with locally advanced or metastatic NSCLC with RET gene fusion detected by an FDA‑approved test are eligible for coverage.RET fusion detected by FDA‑approved test

    Coverage duration 1 year; prior therapy history required where applicable.

    Retevmo — MTC and other RET‑altered tumors: Adult and pediatric patients (>=2 years) with RET‑mutant medullary thyroid cancer requiring systemic therapy, and locally advanced/metastatic solid tumors with RET fusion after progression on prior systemic therapy, are eligible per product criteria.RET mutation/fusion detected by FDA‑approved test; progression where specified

    Prerequisite Part D therapy flag applies in some settings.

    Posaconazole DR - Prophylaxis and treatment

    Posaconazole DR coverage (prophylaxis and treatment) requires trials of alternatives:

    Posaconazole prophylaxis: Prophylaxis of invasive fungal infections for high‑risk patients (e.g., HSCT with GVHD or hematologic malignancy with prolonged neutropenia) or for secondary prophylaxis after prior fungal infection: requires trial with two of fluconazole, itraconazole, or voriconazole prior to posaconazole approval.trial of two alternative azoles

    Coverage duration 6 months for listed contexts; prerequisite Part D therapy required.

    Posaconazole treatment: Treatment of invasive fungal infections caused by Aspergillus or Candida: requires trial with two listed alternatives prior to approval.trial of two alternatives

    NASH/MASH Initial Coverage

    Initial coverage prerequisites for NASH/MASH:

    NASH/MASH initial coverage prerequisites: Diagnosis of noncirrhotic NASH or MASH AND presence of advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive assessment AND trial of semaglutide prior to initiation.F2–F3 fibrosis

    Coverage duration 1 year; renewal requires no progression to cirrhosis and evidence of benefit.

    Rinvoq Coverage Criteria

    Rinvoq coverage is indication‑specific; examples summarized below:

    Rinvoq — rheumatoid arthritis (RA): Moderately to severely active RA AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine). In some settings, inadequate response/intolerance to one or more TNF inhibitors is required or documentation that a trial is inappropriate.

    Reauthorization requires documentation of positive clinical response and no combination with potent immunosuppressant.

    Rinvoq — other indications: Psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, non‑radiographic axial spondyloarthritis: each indication requires diagnosis per product line and trials of conventional therapies (e.g., NSAID for AS); TNF‑inhibitor trials may be required where noted.

    Coverage duration 1 year; prerequisite Part D therapy required where indicated.

    Rybrevant Coverage Criteria

    Covered when specific prior‑therapy or progression criteria are met:

    Rybrevant — EGFR exon 20 insertion NSCLC: Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation AND disease progression on or after platinum‑based chemotherapy.

    Coverage duration 1 year.

    Rybrevant — other EGFR mutations: Locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation whose disease progressed on or after an EGFR TKI requires combination use with carboplatin and pemetrexed per specified settings.

    Product-specific coverage conditions (partial list)

    Product‑specific coverage conditions (partial list) — representative entries:

    Sunitinib (GIST): Coverage for GIST requires disease progression on or intolerance to imatinib mesylate; prescribed by an oncologist.

    Coverage duration 1 year.

    Tafinlar (dabrafenib): Unresectable/metastatic melanoma with BRAF V600E or V600K mutation: requires trial of vemurafenib + cobimetinib used in combination; certain indications require use in combination with trametinib; progression following prior treatment required for some solid tumors.

    Coverage duration 1 year; liquid formulation requires inability to swallow tablets.

    Tagrisso (osimertinib): EGFR exon 19 deletion or exon 21 L858R NSCLC: use as adjuvant after resection, first‑line metastatic, or first‑line with pemetrexed+platinum chemotherapy; EGFR T790M coverage requires progression on or after prior EGFR TKI therapy.

    Coverage duration 1 year.

    Tocilizumab: RA: diagnosis of moderately to severely active RA AND trial of two of specified agents (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia); reauthorization requires documentation of positive clinical response; cannot be used in combination with another biologic/targeted DMARD for same condition.

    Coverage duration 1 year.

    Tetrabenazine: Coverage excluded for patients with hepatic impairment, active suicidality, untreated/inadequately treated depression, or concurrent MAOI or reserpine use; CYP2D6 genotype documentation required for doses >50 mg/day.

    Coverage duration 1 year.

    Verzenio-related PI3K/AKT/PTEN altered breast cancer

    Covered when ALL of the following are met for HR‑positive, HER2‑negative locally advanced or metastatic breast cancer with specified alterations:

    PI3K/AKT/PTEN altered breast cancer: Diagnosis of HR‑positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations AND disease progression on at least one endocrine‑based regimen AND use in combination with fulvestrant.

    Coverage duration one year; prerequisite Part D therapy required.

    Verquvo (vericiguat) criteria

    Verquvo coverage requires ALL of the following:

    Heart failure class and EF: Diagnosis of chronic heart failure NYHA class II–IV AND left ventricular ejection fraction (LVEF) <45%.LVEF < 45%
    Recent decompensation: Either previous hospitalization for heart failure within the prior 6 months OR outpatient IV diuretic treatment for heart failure within the prior 3 months.
    Concurrent guideline‑directed medical therapy (GDMT): Must be taken in combination with at least two of: (1) a beta‑blocker (metoprolol succinate, carvedilol, bisoprolol), (2) an ACE inhibitor/ARB/ARNI, (3) an SGLT2 inhibitor approved for heart failure, (4) a mineralocorticoid receptor antagonist unless contraindicated or not tolerated.

    Coverage duration 1 year.

    Tymlos (abaloparatide) criteria

    Tymlos coverage requires ALL of the following:

    Bone mineral density: Documentation of bone mineral density T‑score ≤ -2.5.T-score ≤ -2.5
    Prior therapy: Trial of both: 1) JUBBONTI or STOBOCLO AND 2) either an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage also provided if the patient is unable to be treated with all listed agents.

    Ubrelvy (ubrogepant) criteria

    Ubrelvy for acute migraine is covered when ALL of the following are met:

    Ubrelvy step requirement: Trial of at least two generic triptans (e.g., sumatriptan, rizatriptan) prior to Ubrelvy, unless triptan therapy is contraindicated, not tolerated, or clinically inappropriate due to comorbidities.trial of 2 triptans

    Coverage duration 1 year.

    Winrevair (prostacyclin analog / combination) criteria

    Winrevair coverage for pulmonary arterial hypertension requires ALL of the following:

    Winrevair prior therapies: Trial of both: 1) generic sildenafil or tadalafil AND 2) generic bosentan or ambrisentan prior to Winrevair initiation.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Vowst (fecal microbiota, live-jslm) coverage duration

    Vowst coverage is defined by treatment course:

    Vowst treatment course: Coverage duration specified as 60 days (defined course per product labeling).60 days

    No prerequisite Part D drug required.

    Vosevi (hepatitis C) guidance

    Vosevi coverage follows specialty guidance:

    Vosevi (HCV): Criteria will be applied consistent with current AASLD/IDSA guidance for HCV treatment.

    Coverage duration 1 year; follow guideline‑recommended regimens.

    Welireg (belzutifan) criteria

    Welireg coverage includes indication‑specific prior‑therapy requirements:

    Welireg — VHL disease and associated tumors: Coverage for VHL disease patients who require therapy for associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumors per product labeling.

    For advanced RCC with clear‑cell component requires prior PD‑1/PD‑L1 inhibitor and VEGF‑TKI.

    Xeljanz/tofacitinib and related agents

    JAK inhibitors and related immune‑modulating agents are covered when indication‑specific prior therapy conditions are met:

    Xeljanz/tofacitinib and related agents: Indication‑specific prior therapy requirements (e.g., RA: trial of one DMARD; JIA: trial and failure/intolerance to one NSAID; UC: diagnosis of moderately to severely active disease). For certain indications, inadequate response or intolerance to one or more TNF inhibitors is required. Concomitant use with potent immunosuppressants (e.g., azathioprine, cyclosporine) or another biologic/targeted DMARD for the same condition is prohibited; reauthorization requires documentation of positive clinical response and no prohibited combination.

    Coverage duration typically 1 year; prerequisite Part D therapy required where indicated.

    Xdemvy (lotilaner) criteria

    Covered when ALL of the following are documented:

    Xdemvy (Demodex blepharitis): Confirmation of Demodex blepharitis diagnosis via presence of collarettes on slit‑lamp examination prior to treatment initiation.

    Coverage duration 1 year.

    Verquvo concurrent therapy

    Verquvo must be used with appropriate background therapy:

    Verquvo concurrent therapy requirement: Must be taken in combination with at least two guideline‑directed medical therapy agents (see GDMT list) unless contraindicated or not tolerated.

    See Verquvo tumor entry for diagnostic/event requirements.

    Tukysa (tucatinib) colorectal cancer criteria

    Tukysa coverage for colorectal cancer requires ALL of the following:

    Tukysa — RAS wild‑type HER2‑positive CRC: RAS wild‑type, HER2‑positive unresectable or metastatic colorectal cancer: trial of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy AND combination therapy with trastuzumab is required prior to Tukysa.

    Coverage duration one year; prerequisite Part D therapy required.

    Prerequisite Part D drug note

    Note regarding prerequisite Part D medication requirement:

    Prerequisite Part D drug note: Some listed products require the use of a prerequisite Part D drug prior to coverage while others do not; verify per individual product line.

    See product‑specific entries for details.

    Pazopanib hydrochloride criteria

    Covered when ALL of the following are met:

    Pazopanib for STS: Coverage for advanced soft tissue sarcoma (STS) requires prior treatment with chemotherapy and prescribed by an oncologist.

    Coverage duration one year; prerequisite Part D therapy required.

    Voydeya (pegcetacoplan) EVH criteria

    Voydeya coverage for PNH‑related EVH requires ALL of the following:

    Voydeya laboratory thresholds: Clinically significant extravascular hemolysis (EVH) due to PNH with hemoglobin ≤ 9.5 g/dL AND absolute reticulocyte count ≥ 120 × 10^9/L.Hgb ≤ 9.5 g/dL; ARC ≥ 120 × 10^9/L

    Requires combination use with SOLIRIS or ULTOMIRIS only; coverage duration 1 year.

    Voquezna (vonoprazan-containing packs) H. pylori criteria

    Voquezna multi‑pack coverage for H. pylori requires ALL of the following:

    Voquezna H. pylori coverage: Diagnosis of Helicobacter pylori infection AND trial of a guideline‑recommended, generic first‑line H. pylori regimen (e.g., clarithromycin triple therapy or bismuth quadruple therapy) prior to Voquezna use.

    Coverage duration 1 year; prerequisite Part D drug required.

    General prior authorization criteria (grouped)

    General prior authorization criteria grouped across many products:

    General prior authorization prerequisites: Diagnosis appropriate to the requested indication AND trial and inadequate response or intolerance to one or more specified prior therapies as listed for the product (e.g., trial of a DMARD for RA; trial of an NSAID for AS); not to be used in combination with a potent immunosuppressant or another biologic/targeted DMARD for the same condition where prohibited.

    See individual product entries for the specific prior therapies and diagnostic evidence required.

    TNF inhibitor prerequisite

    TNF‑inhibitor prerequisite where specified:

    TNF inhibitor requirement: For certain indications coverage requires inadequate response or intolerance to one or more TNF inhibitors (e.g., etanercept, adalimumab biosimilars) OR documentation that a TNF‑inhibitor trial is inappropriate.

    Applies where indicated in product‑specific lines.

    Xolair - Allergic asthma

    Xolair coverage for allergic asthma requires ALL of the following:

    Xolair — allergic asthma: Diagnosis of uncontrolled moderate to severe allergic asthma with positive skin test or in‑vitro reactivity to a perennial aeroallergen AND serum IgE within age‑specific range AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of an additional controller (leukotriene modifier, LABA, or LAMA).IgE thresholds per age band

    Reauthorization requires documentation of positive clinical response.

    Xolair - CSU and CRSwNP

    Xolair other indications covered when the following are met:

    Xolair — chronic spontaneous urticaria (CSU): Diagnosis of CSU with symptoms despite H1 antihistamine treatment AND trial of at least one second‑generation antihistamine.

    Reauthorization requires positive clinical response.

    Xolair — CRSwNP: Diagnosis of chronic rhinosinusitis with nasal polyposis with recurring polyps despite intranasal corticosteroids.

    Reauthorization requires positive clinical response.

    Xermelo - Carcinoid syndrome diarrhea

    Covered when ALL of the following are met:

    Xermelo — carcinoid syndrome diarrhea: Trial of somatostatin analog therapy (e.g., octreotide, lanreotide) is required prior to Xermelo initiation.

    Coverage duration 1 year.

    Xifaxan - indication-specific prerequisites

    Covered when prerequisite trials applicable to each indication are documented:

    Xifaxan 550 mg prerequisites: Hepatic encephalopathy: trial of lactulose required. IBS‑D: trial of at least one of loperamide, dicyclomine, or diphenoxylate/atropine. Recurrent C. difficile: trial of vancomycin required.

    Coverage duration 1 year.

    Xpovio - hematologic oncology prerequisites

    Xpovio coverage requires prior therapy history per hematologic indication:

    Xpovio — multiple myeloma: Coverage for relapsed/refractory multiple myeloma requires at least four prior therapies including specified classes (≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and an anti‑CD38 monoclonal antibody) where indicated; for some MM settings failure of one prior therapy may suffice per product line.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Xpovio — DLBCL: Relapsed or refractory diffuse large B‑cell lymphoma: requires trial of at least two lines of systemic therapy prior to approval.

    Prostate cancer - abiraterone prerequisite

    Prostate cancer agents and abiraterone prerequisite:

    Xtandi coverage prerequisite: Coverage for CRPC, MCRPC, MCSPC, and high‑risk nonmetastatic prostate cancer requires prior trial of abiraterone (250 mg tablet strength) per product line.

    Coverage duration 1 year; prerequisite Part D therapy required.

    Yonsa coverage prerequisite: Coverage requires trial of abiraterone 250 mg prior to Yonsa use as specified.

    Coverage duration 1 year.

    Zonisade - seizure disorder

    Zonisade coverage requires ONE of the following:

    Zonisade — seizure disorder: Trial of at least two generic anticonvulsants, one of which must be generic zonisamide, OR patient is unable to swallow tablets/capsules.

    Coverage duration 1 year.

    Zurzuvae - postpartum depression

    Zurzuvae coverage requires ALL of the following:

    Zurzuvae — postpartum depression: Diagnosis of postpartum depression with onset in the third trimester or within 4 weeks postpartum AND member is currently ≤12 months postpartum.

    Coverage duration 60 days.

    Medicare Part B/Part D determination

    Medicare Part B vs Part D coverage determination:

    Part B/Part D determination: Some drugs may be covered under Medicare Part B or Part D depending on circumstances; submission of information describing the use and setting (site of care) may be required to determine correct payment/coverage classification.

    Examples: infusion vs outpatient administration may affect determination.

    Abilify Asimtufii - prerequisite

    Covered when ALL of the following are met:

    Abilify Asimtufii prerequisite: Requires trial of oral aripiprazole prior to coverage; coverage duration is lifetime.

    See product entry for documentation requirements.

    Abilify Maintena - Initial

    Initial therapy requirement:

    Abilify Maintena initial: Requires documented trial of oral aripiprazole prior to Invega Maintena initiation; coverage duration is lifetime.

    Refer to product line for required documentation.

    Exxua / Trintellix - Initial

    Initial therapy requirement:

    Exxua / Trintellix initial: Requires trial of at least two listed generic antidepressants (e.g., bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, etc.) prior to Exxua/Trintellix initiation.trial of 2 generics

    Coverage duration lifetime.

    Multiple antipsychotics - Initial

    Initial therapy requirement for listed antipsychotic agents:

    Multiple antipsychotics initial requirement: Requires trial of at least one listed generic antipsychotic agent (examples provided in product entry) prior to coverage of Caplyta, Rexulti, Vraylar CAPS, or Zyprexa Relprevv.

    Coverage duration lifetime.

    Aristada - Initial

    Initial coverage requirement:

    Aristada initial: Requires trial or documented intolerance to Abilify Maintena or oral aripiprazole prior to Aristada initiation; coverage duration lifetime.

    Documentation of trial or intolerance required.

    Aristada Initio - Initial

    Initial coverage requirement:

    Aristada Initio initial: Requires trial of oral aripiprazole prior to Aristada Initio initiation; coverage duration lifetime.

    Documentation required per product entry.

    Wound care supplies - Initial

    Wound care supplies initial coverage requires:

    Wound care supplies coverage: Submission of a claim for an insulin product within the prior 180 days is required for coverage of specified wound care pads/gauze products.insulin claim within last 180 days

    Coverage duration 1 year.

    Invega Hafyera - Initial

    Initial therapy requirement:

    Invega Hafyera initial: Requires trial of a once‑monthly paliperidone palmitate extended‑release injectable for at least 4 months OR an every‑three‑month paliperidone palmitate extended‑release injectable for at least one three‑month cycle prior to Invega Hafyera initiation.4 months monthly LAI OR one 3‑month cycle of 3‑month LAI

    Coverage duration lifetime.

    Invega Sustenna - Initial

    Initial therapy requirement:

    Invega Sustenna initial: Requires trial of oral paliperidone or oral risperidone prior to Invega Sustenna initiation; coverage duration lifetime.

    Documentation of prior trial required.

    Invega Trinza - Initial

    Initial therapy requirement:

    Invega Trinza initial: Requires trial of oral paliperidone or oral risperidone prior to Invega Trinza initiation; coverage duration lifetime.

    Documentation required per product entry.

    Rhopressa - Listing

    Listing note:

    Rhopressa listing: Product listed without additional criteria in this segment; see product entry for any prior‑therapy or trial requirements.

    Risperidone ER / Paliperidone requirements

    Covered when ALL of the following are met:

    Risperidone ER / paliperidone requirements: Requires trial of oral risperidone or oral paliperidone prior to coverage of listed long‑acting injectable formulations.

    Coverage duration lifetime.

    Ophthalmic agents (Rhopressa, Rocklatan)

    Covered when ALL of the following are met:

    Ophthalmic glaucoma agents (Rhopressa, Rocklatan): Requires trial of any generic formulary ophthalmic glaucoma medication OR Lumigan prior to coverage of Rhopressa or Rocklatan.

    Coverage duration 1 year.

    Rytary prior therapy

    Covered when ALL of the following are met:

    Rytary prior therapy: Requires trial of generic oral extended‑release carbidopa/levodopa prior to Rytary approval.

    Coverage duration 1 year.

    SGLT2 inhibitors step therapy and exception

    Covered when ALL of the following are met (step‑therapy exception noted):

    SGLT2 inhibitors step therapy and exception: Farxiga requires trial of generic dapagliflozin prior to coverage. Jardiance requires trial of generic dapagliflozin except when requested to reduce risk of cardiovascular death in adults with T2DM and established cardiovascular disease (exception applies).

    Coverage durations vary by product.

    Febuxostat prior therapy

    Covered when ALL of the following are met:

    Febuxostat prior therapy: Requires trial of allopurinol OR documented contraindication to allopurinol prior to febuxostat initiation.

    Coverage duration lifetime.

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    Prior authorization required for listed drugs

    Prior authorization (PA) is required for drugs listed in this formulary; PA-designated drugs appear with (PA) and require that clinical and/or administrative criteria are documented before coverage is provided. Providers should submit the required clinical information and use the pharmacy help desk to request PA when needed.

    Prior Authorization

    Adbry — PA criteria and reauthorization

    Adbry (dupilumab) initial coverage requires the patient be ≥12 years with moderate to severe atopic dermatitis and have trialed and failed one of the specified topical/systemic therapies; reauthorization requires documentation of positive clinical response and dosing limits apply for patients <100 kg after 16 weeks unless clinical rationale supports continued every‑2‑week dosing.

    • Age ≥ 12 years; diagnosis of moderate to severe atopic dermatitis
    • Trial and failure of one: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil
    • Reauthorization: documentation of positive clinical response; dose limited to 300 mg every 4 weeks for patients <100 kg who respond after 16 weeks unless rationale provided
    Prior Authorization

    PA required; typical 1‑year authorization

    Most specialty products in this list require prior authorization; authorization durations are typically set to one year and many products require documentation of prior therapies or trials per the product entry.

    • Coverage durations commonly 1 year (some products LIFETIME or other specific durations)
    • Provider must document prerequisite therapy trials when required by the product entry
    Prior Authorization

    PA and duration — Part D specialty drugs

    Part D specialty drugs listed require PA with coverage durations commonly one year (some lifetime); many entries also flag prerequisite Part D drug requirements that must be met and documented by the provider.

    • Submit documentation of required prior therapies or diagnostic confirmation as specified per product
    • Coverage duration and prerequisite Part D drug requirements vary by product
    Prior Authorization

    Iclusig — PA specifics and duration

    Iclusig (ponatinib) prior authorization requires indication‑specific documentation; coverage duration is one year and specific rules apply (e.g., combination with chemotherapy for newly diagnosed Ph+ ALL; monotherapy permitted for T315I‑positive disease when no other kinase inhibitors are indicated).

    • Coverage duration: 1 year
    • Newly diagnosed Ph+ ALL: use in combination with chemotherapy
    • T315I‑positive Ph+ ALL or CML: monotherapy when no other kinase inhibitors indicated; prior therapy trials required for other CP CML indications
    Documentation Required

    IVIG — inability to use oral formulation required

    IVIG products are subject to Part B vs Part D review; coverage for listed IVIG products requires that the patient is unable to swallow tablet formulation or unable to achieve the prescribed dose with tablet formulation, and coverage durations are commonly one year.

    • Provider must document inability to swallow tablet formulation or inability to achieve prescribed tablet dose
    • IVIG subject to Part B vs Part D determination
    Prior Authorization

    Kevzara — PA, trial and combination rules

    Kevzara (sarilumab) prior authorization requires trials of two of the listed alternatives for RA, documentation of positive clinical response for reauthorization, and Kevzara cannot be used in combination with another biologic/targeted DMARD indicated for the same condition.

    • RA: trial of two of Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, or Orencia
    • Reauthorization: documentation of positive clinical response
    • Do not combine with another biologic/targeted DMARD for the same condition
    Prior Authorization

    Liraglutide — PA and documentation

    Liraglutide PA requires submission of medical records confirming a diagnosis of type 2 diabetes mellitus or qualifying laboratory evidence (A1c ≥ 6.5% or FPG ≥ 126 mg/dL or 2‑hr PG ≥ 200 mg/dL); liraglutide is excluded when used for weight‑loss only.

    • Submit medical records confirming T2DM or lab evidence (A1c ≥ 6.5% OR FPG ≥ 126 mg/dL OR 2‑hr PG ≥ 200 mg/dL)
    • Excluded if used solely for weight loss
    Prior Authorization

    PA required; typical 1‑year duration

    Prior authorization is required for many products and coverage durations are commonly one year; providers must follow product‑specific prerequisite therapy rules and submit supporting documentation.

    • Coverage duration commonly 1 year
    • Document prerequisite therapy trials when indicated
    Prior Authorization

    Mavyret — apply AASLD/IDSA guidance for PA

    Mavyret prior authorization decisions are applied consistent with current AASLD/IDSA guidance; providers should document therapy per those society recommendations when requesting PA.

    • Follow current AASLD/IDSA guidance for HCV treatment when submitting PA
    Prior Authorization

    PA required — follow product entries for details

    Prior authorization is required for the specialty products listed; providers must document product‑specific prerequisite therapies or condition evidence as noted in each product entry when requesting authorization.

    • Submit product‑specific clinical documentation and prior therapy history as required
    Prior Authorization

    Posaconazole DR — PA and required azole trials

    Posaconazole delayed‑release (DR) requires prior authorization; for prophylaxis the provider must document trials of two alternative azoles (fluconazole, itraconazole, or voriconazole), and for treatment also trials of two listed alternatives are required.

    • Prophylaxis: trial of two of fluconazole, itraconazole, voriconazole
    • Treatment: trial of two listed alternatives prior to posaconazole DR
    Prior Authorization

    Rezdiffra — NASH/MASH PA and renewal

    Rezdiffra (for NASH/MASH) prior authorization requires verification of advanced liver fibrosis (stage F2–F3) by FibroScan or other imaging‑based noninvasive assessment; coverage also requires a prior trial of semaglutide and renewal requires no progression to cirrhosis and specified improvement/stabilization criteria.

    • Document FibroScan or other imaging‑based noninvasive evidence of F2–F3 fibrosis
    • Trial of semaglutide required before approval
    • Renewal: patient has not progressed to cirrhosis and shows NASH/MASH resolution, ≥1‑stage fibrosis improvement without NASH worsening, or imaging/blood‑based evidence of improvement/stabilization
    Prior Authorization

    Retevmo — molecular testing and PA

    Retevmo requires prior authorization; providers must document RET gene fusion or RET mutation detected by an FDA‑approved test and prior therapy history where applicable (e.g., progression after prior systemic treatment for RET‑fusion solid tumors).

    • Submit molecular testing showing RET fusion or RET mutation by an FDA‑approved test
    • Document prior systemic therapy and progression when indicated
    Step Therapy

    NASH/MASH — semaglutide trial and renewal requirements

    Coverage for NASH/MASH (Rezdiffra) requires a documented trial of semaglutide prior to approval; reauthorization requires that the patient has not progressed to cirrhosis and demonstrates specified improvement or stabilization.

    • Prior semaglutide trial required
    • Reauthorization: no progression to cirrhosis plus improvement/resolution or stabilization per imaging or blood‑based assessment
    Prior Authorization

    Rinvoq — PA and prerequisite therapy

    Rinvoq (upadacitinib) coverage requires trials of specified conventional therapies per indication (e.g., one DMARD for RA; an NSAID for AS), may require trial/failure of TNF inhibitors for some indications, and reauthorization requires documentation of positive clinical response and no combination with potent immunosuppressants.

    • RA: trial of one DMARD required
    • AS: trial of an NSAID required
    • For several indications, trial/failure of TNF inhibitor(s) required unless inappropriate
    • Reauthorization: documentation of positive clinical response; do not combine with potent immunosuppressants
    Prior Authorization

    Rybrevant — PA and prior progression requirement

    Rybrevant coverage for EGFR exon 20 insertion NSCLC requires disease progression on or after platinum‑based chemotherapy; for other EGFR mutation settings coverage may require prior EGFR TKI and combination chemotherapy per the product entry.

    • EGFR exon 20 insertion NSCLC: progression on/after platinum chemotherapy required
    • Other EGFR mutation indications: prior EGFR TKI and specified combination chemotherapy may be required
    Prior Authorization

    General PA — follow product-specific requirements

    Many products require prior authorization with coverage durations typically set to one year and may require prerequisite Part D therapies or diagnostic documentation; providers must follow each product's entry for exact submission requirements.

    • Check individual product entries for exact prerequisite therapies and documentation
    • Common coverage duration: 1 year
    Prior Authorization

    Tagrisso — PA specifics and indications

    Tagrisso (osimertinib) coverage requires use as adjuvant therapy after resection, as first‑line in metastatic disease, or in specified combinations (e.g., with pemetrexed and platinum chemotherapy); EGFR T790M coverage requires progression on or after an EGFR TKI.

    • Adjuvant after resection or first‑line metastatic use per labeling
    • EGFR T790M: requires progression on/after EGFR TKI therapy
    • Certain stage III patients post‑chemoradiation also covered per entry
    Prior Authorization

    Tafinlar — PA, combination and formulation specifics

    Tafinlar (dabrafenib) prior authorization for unresectable/metastatic melanoma with BRAF V600E or V600K mutation requires a trial of vemurafenib plus cobimetinib used in combination; several indications require combination use with trametinib and liquid formulation coverage requires inability to swallow tablets.

    • Trial of vemurafenib + cobimetinib required for certain melanoma indications
    • Some indications require combination with trametinib
    • Liquid formulation: coverage requires inability to swallow tablets
    Prior Authorization

    Tocilizumab — PA and reauthorization criteria

    Tocilizumab prior authorization for RA requires diagnosis of moderately to severely active RA and trial of two specified biologic/targeted agents (e.g., Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia); reauthorization requires documentation of positive clinical response and combination with another biologic for the same condition is not permitted.

    • Trial of two of Enbrel, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia required
    • Reauthorization: documentation of positive clinical response
    • Do not combine with another biologic/targeted DMARD for the same condition
    Prior Authorization

    PI3K/AKT/PTEN‑altered breast cancer — PA requirements

    Coverage for HR‑positive, HER2‑negative advanced/metastatic breast cancer with PIK3CA/AKT1/PTEN alterations requires progression on at least one endocrine‑based regimen and combination use with fulvestrant; providers must document prior endocrine therapy and molecular testing per product guidance.

    • Progression on ≥1 endocrine‑based regimen or recurrence within 12 months of adjuvant therapy
    • Must be used in combination with fulvestrant
    • Document molecular testing for alterations as applicable
    Prior Authorization

    Tucatinib — PA and combination therapy requirements

    Tucatinib (Tukysa) prior authorization for HER2‑positive advanced unresectable or metastatic breast cancer requires trial of one or more prior anti‑HER2 regimens and combination with trastuzumab and capecitabine; for RAS wild‑type HER2‑positive metastatic CRC the provider must document prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy and combination with trastuzumab.

    • Document prior anti‑HER2 regimen(s)
    • Tucatinib requires combination with trastuzumab and capecitabine for breast cancer
    • CRC: document prior chemotherapy regimens and trastuzumab combination
    Prior Authorization

    Assorted products — PA required

    Several products (Vitrakvi, Vigabatrin, Vizimpro, Vonjo, etc.) require prior authorization with typical 1‑year coverage; submit product‑specific documentation per each entry when requesting PA.

    • Coverage duration typically 1 year
    • Follow each product's entry for required clinical information
    Prior Authorization

    PA required — document prerequisite trials

    Prior authorization is required for many Part D drugs in the list; providers must document prerequisite therapy trials as specified in individual product lines when submitting PA requests.

    • Document prior therapy trials or contraindications where required
    • Check each product entry for exact PA submission requirements
    Prior Authorization

    Abilify Maintena — oral aripiprazole trial required

    Abilify Maintena prior authorization requires documentation of a trial of oral aripiprazole; coverage duration is lifetime.

    • Trial of oral aripiprazole required
    • Coverage duration: LIFETIME
    Step Therapy

    Exxua / Trintellix — antidepressant trial requirement

    Exxua (including Exxua Titration Pack) and Trintellix require prior authorization with documented trials of at least two listed generic antidepressants; coverage duration is lifetime.

    • Trial of ≥2 listed generic antidepressants required
    • Coverage duration: LIFETIME
    Step Therapy

    Atypical antipsychotics — prior antipsychotic trial required

    Atypical antipsychotic agents (Caplyta, Rexulti, Vraylar CAPS, Zyprexa Relprevv) require prior authorization with a trial of at least one listed generic antipsychotic agent; coverage durations are lifetime.

    • Trial of ≥1 listed generic antipsychotic required
    • Coverage duration: LIFETIME
    Prior Authorization

    Aristada — PA: trial or intolerance to Abilify Maintena/oral aripiprazole

    Aristada prior authorization requires trial or intolerance to Abilify Maintena or oral aripiprazole; coverage duration is lifetime.

    • Trial or documented intolerance to Abilify Maintena or oral aripiprazole required
    • Coverage duration: LIFETIME
    Step Therapy

    Aristada Initio — oral aripiprazole trial required

    Aristada Initio prior authorization requires a trial of oral aripiprazole; coverage duration is lifetime.

    • Trial of oral aripiprazole required
    • Coverage duration: LIFETIME
    Billing Rule

    Wound care supplies — PA and insulin claim requirement

    Selected wound care pads/gauze require prior authorization and a claim for an insulin product within the last 180 days; coverage duration is one year.

    • Submit claim history documenting an insulin product claim within prior 180 days
    • Coverage duration: 1 year
    Step Therapy

    Invega Hafyera — LAI trial requirement

    Invega Hafyera prior authorization requires trial of a once‑monthly paliperidone palmitate LAI for at least four months OR an every‑three‑month paliperidone palmitate LAI for at least one three‑month cycle; coverage duration is lifetime.

    • Trial of monthly paliperidone palmitate for ≥4 months OR 3‑month paliperidone palmitate for ≥1 cycle required
    • Coverage duration: LIFETIME
    Step Therapy

    Invega Sustenna — oral antipsychotic trial required

    Invega Sustenna prior authorization requires a trial of oral paliperidone or oral risperidone before approval; coverage duration is lifetime.

    • Trial of oral paliperidone or oral risperidone required
    • Coverage duration: LIFETIME
    Step Therapy

    Invega Trinza — oral antipsychotic trial required

    Invega Trinza prior authorization requires trial of oral paliperidone or oral risperidone; coverage duration is lifetime.

    • Trial of oral paliperidone or oral risperidone required
    • Coverage duration: LIFETIME
    Step Therapy

    Rhopressa — trial of generic ophthalmic glaucoma med required

    Rhopressa is listed as a formulary product affected; coverage requires trial of a generic formulary ophthalmic glaucoma medication or Lumigan prior to approval per the ophthalmic agents entry.

    • Trial of a generic formulary ophthalmic glaucoma medication or Lumigan required
    • Coverage duration: 1 year (per ophthalmic agents rules)
    Step Therapy

    SGLT2 step therapy and cardiovascular exception

    SGLT2 step therapy: Farxiga requires trial of generic dapagliflozin prior to coverage; Jardiance requires trial of generic dapagliflozin except when requested to reduce risk of cardiovascular death in adults with T2DM and established cardiovascular disease.

    • Farxiga: trial of generic dapagliflozin required
    • Jardiance: trial of generic dapagliflozin required except for the cardiovascular death risk reduction indication
    Step Therapy

    Rytary — prior trial of generic ER carbidopa/levodopa

    Rytary prior authorization requires documentation of a trial of generic oral extended‑release carbidopa/levodopa prior to approval.

    • Trial of generic ER carbidopa/levodopa required before Rytary
    Step Therapy

    Step therapy process — provider must document prior trials

    Drugs subject to step therapy require prior treatment with one or more formulary drugs before coverage; ST‑designated drugs are identified in the formulary with (ST) and providers must document prior trials or contraindications.

    • Submit documentation of prior trial(s) or contraindication(s) for ST requests
    • ST‑designated drugs require following the step sequence listed
    Step Therapy

    Cancer agents — prerequisite therapy documentation

    Cancer targeted agents (e.g., Braftovi, Cabometyx) require prior or combination therapy per indication — providers must document prior agents or combination regimens (e.g., vemurafenib + cobimetinib for BRAF‑mutant melanoma; sorafenib trial for HCC with Cabometyx).

    • Braftovi: document trial/combination per indication (vemurafenib + cobimetinib; cetuximab + 5‑FU for CRC, etc.)
    • Cabometyx: first‑line RCC requires combination with nivolumab; HCC requires prior sorafenib
    Step Therapy

    Step therapy — required prior medication trials

    Many products require trials of specific prior therapies before approval (examples include: two second‑generation antipsychotics for schizophrenia; two triptans for acute migraine agents; trials of DMARDs for rheumatologic biologics) — providers must document the specified trials or intolerances.

    • Schizophrenia: trial of two second‑generation antipsychotics
    • Migraine acute agents: trial of two triptans unless contraindicated
    • Rheumatologic biologics: trial of DMARDs or TNF inhibitors where specified
    Note
    Note
    Note
    Note
    Note
    Step Therapy

    Posaconazole DR — two alternative azoles required

    Posaconazole prophylaxis requires documentation that the patient has trialed two alternative azoles (fluconazole, itraconazole, or voriconazole) prior to approval.

    • Document trials of two alternatives among fluconazole, itraconazole, voriconazole for prophylaxis
    Step Therapy

    Rezdiffra — semaglutide trial required

    Rezdiffra requires a prior trial of semaglutide before approval; providers must document the semaglutide trial when requesting coverage.

    • Document prior semaglutide trial
    Step Therapy

    Lumakras — prior therapy and combination requirements

    Lumakras (sotorasib) coverage for KRAS G12C‑mutated NSCLC requires trial of at least one prior systemic therapy; for KRAS G12C mCRC after prior chemotherapy, combination with panitumumab is required — document prior systemic therapies and combination intent.

    • NSCLC: trial of ≥1 prior systemic therapy required
    • mCRC: prior fluoropyrimidine/oxaliplatin/irinotecan chemotherapy and combination with panitumumab required
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Prolastin‑c — required diagnostic documentation

    Providers must submit diagnostic documentation for Prolastin‑c coverage: congenital alpha‑1 antitrypsin deficiency consistent with phenotypes (PIZZ, PIZ (NULL) or PI (NULL,NULL)), symptomatic emphysema, FEV1 < 80% predicted, and patient age ≥18 years.

    • Document congenital AAT deficiency phenotype (e.g., PIZZ, PIZ (NULL))
    • Symptomatic emphysema and FEV1 < 80% predicted
    • Age ≥ 18 years
    Documentation Required

    Dalfampridine — T25FW documentation and exclusion

    Dalfampridine requires submission of a baseline timed 25‑foot walk (T25FW) prior to initiation; reauthorization requires documentation of stability or improvement on the T25FW; dalfampridine is excluded for patients who are wheelchair‑bound or become wheelchair‑bound.

    • Submit baseline T25FW prior to initiation
    • Reauthorization: document stability or improvement on T25FW
    • Excluded if patient is or becomes wheelchair‑bound
    Documentation Required

    Dupixent and related biologics — documentation requirements

    Dupixent and related biologics require documentation of diagnosis, age/weight minimums per indication, trial and failure of specified prior therapies, and evidence of positive clinical response for reauthorization.

    • Document diagnosis and applicable age/weight thresholds per indication
    • Document trial/failure of required prior therapies (e.g., topical/systemic agents for AD)
    • Reauthorization: documentation of positive clinical response
    Documentation Required

    L‑glutamine — crisis history and hydroxyurea trial documentation

    L‑glutamine coverage requires documentation that the patient experienced two or more sickle cell–related crises in the past 12 months and trial of or intolerance to hydroxyurea.

    • Document ≥2 sickle cell crises in prior 12 months
    • Document trial of or intolerance to hydroxyurea
    Documentation Required

    Diabetes documentation — lab confirmation required

    For diabetes agents requiring PA (e.g., liraglutide), submit medical records confirming T2DM diagnosis or laboratory evidence (A1c ≥ 6.5%, FPG ≥ 126 mg/dL, or 2‑hr PG ≥ 200 mg/dL) when requesting authorization.

    • Provide chart notes or lab values confirming T2DM per listed thresholds
    Documentation Required

    EGPA — required diagnostic documentation

    EGPA coverage documentation must include two typical EGPA clinical/pathologic features (examples: histopathology showing eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, or ANCA positivity).

    • Provide documentation of two typical EGPA features as listed
    • Include supporting pathology, imaging, or clinical notes
    Documentation Required

    Reauthorization — require documentation of clinical response

    Reauthorization for many biologic indications requires documentation of positive clinical response to therapy; providers must submit outcome measures or clinical notes demonstrating benefit.

    • Submit clinical notes, objective measures, or test results showing improvement or disease control
    Note
    Documentation Required

    Nexletol/Nexlizet — statin trial and LDL documentation

    Nexletol/Nexlizet initiation requires documentation of trial and failure or intolerance to a high‑intensity statin; lack of documentation of a statin trial may lead to denial.

    • Document trial of a high‑intensity statin (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg) unless intolerant
    • Provide recent on‑treatment LDL values when required
    Documentation Required

    Mekinist — mutation testing and formulation documentation

    Mekinist (tablet or liquid) documentation must include BRAF V600E or V600K mutation detected by an FDA‑approved test when indicated; for the liquid formulation also document inability to swallow tablets and prior therapy trials where required (e.g., vemurafenib + cobimetinib).

    • Provide FDA‑approved test result confirming BRAF V600E or V600K mutation
    • If liquid requested, document inability to swallow tablets
    • Document prior therapy trials per indication (e.g., vemurafenib + cobimetinib)
    Documentation Required

    Nucala — disease‑specific documentation and reauth

    For Nucala EGPA coverage, documentation must include two typical EGPA criteria (histopathologic or clinical features) and for HES an eosinophil count and stability on HES therapy; reauthorization requires documentation of positive clinical response.

    • EGPA: document two typical EGPA features
    • HES: eosinophil count ≥1000 cells/µL at initiation and stability on HES therapy
    • Reauthorization: documentation of positive clinical response
    Documentation Required

    Opfolda — diagnostic confirmation required

    Opfolda requires confirmation of diagnosis by serum assay showing decreased acid alpha‑glucosidase activity and genetic testing confirming a GAA mutation; providers must also document symptomatic manifestations and lack of improvement on current ERT.

    • Submit serum assay and genetic testing showing GAA mutation
    • Document symptomatic disease and failure of current ERT
    Documentation Required

    Eltrombopag — baseline platelet count and prior therapy

    Eltrombopag coverage requires baseline platelet count documentation: <30,000/mcL for ITP and <75,000/mcL for thrombocytopenia with chronic hepatitis C; providers must also document prior therapies (corticosteroids, immunoglobulins, or splenectomy) when applicable.

    • Baseline platelet count for ITP: <30,000/mcL
    • Baseline platelet count for chronic hepatitis C thrombocytopenia: <75,000/mcL
    • Document prior therapy trials (corticosteroids, IVIG, or splenectomy) for ITP
    Documentation Required

    Retevmo — molecular testing and prior therapy documentation

    Retevmo coverage requires documentation of RET gene fusion or RET mutation detected by an FDA‑approved test and prior therapy history where applicable (e.g., failure of radioactive iodine for thyroid cancer if appropriate).

    • Provide FDA‑approved molecular test confirming RET fusion/mutation
    • Document prior therapy history and progression as applicable
    Documentation Required

    Praluent — LDL and statin documentation for initiation

    Praluent initiation requires recent on‑treatment LDL values (within 120 days) while on a high‑intensity statin and documentation of prior statin trials or statin intolerance and other confirming criteria for HeFH.

    • Submit LDL while on high‑intensity statin within last 120 days (≥55 mg/dL with ASCVD; >70 mg/dL without ASCVD)
    • Document trial of high‑intensity statin or documented statin intolerance
    Documentation Required

    NASH/MASH — fibrosis staging documentation

    NASH/MASH diagnostic documentation: providers must document diagnosis of NASH or MASH with advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based noninvasive liver disease assessment when requesting Rezdiffra.

    • Provide FibroScan or imaging‑based noninvasive assessment showing F2–F3 fibrosis
    • Document clinical diagnosis of NASH or MASH
    Documentation Required

    Autoimmune disease — prior therapy and documentation

    For rheumatoid arthritis and other autoimmune indications, providers must document diagnosis severity and trials of specified prior therapies (e.g., DMARDs, NSAIDs, and/or TNF inhibitors) when requesting PA for biologics or JAK inhibitors; reauthorization also requires positive clinical response documentation.

    • Document diagnosis severity and specific prior therapy trials (DMARDs, TNF inhibitors, NSAIDs as applicable)
    • Reauthorization: positive clinical response and absence of prohibited combinations
    Documentation Required

    Tetrabenazine — genotype and exclusion documentation

    Documentation of CYP2D6 genotype is required for tetrabenazine doses above 50 mg/day; tetrabenazine is excluded in hepatic impairment, patients actively suicidal or with untreated/inadequately treated depression, and with concurrent MAOI or reserpine use.

    • CYP2D6 genotype documentation for doses >50 mg/day
    • Do not provide in hepatic impairment, active suicidality, untreated/inadequately treated depression, or concurrent MAOI/reserpine use
    Documentation Required

    Tymlos — bone mineral density documentation

    Tymlos coverage requires documentation of bone mineral density T‑score ≤ −2.5; providers must submit the BMD report when requesting authorization.

    • Submit BMD T‑score showing ≤ −2.5
    Documentation Required

    Xdemvy — diagnostic exam required

    Diagnostic exam documentation is required for Xdemvy (lotilaner): confirmation of Demodex blepharitis via presence of collarettes on slit‑lamp exam must be submitted for coverage.

    • Provide slit‑lamp exam findings demonstrating collarettes
    Documentation Required

    Reauthorization — required clinical information

    Reauthorization generally requires documentation of positive clinical response to therapy and, where applicable, confirmation the patient is not receiving contraindicated combination therapy (e.g., tofacitinib with a potent immunosuppressant); providers must submit clinical outcome evidence.

    • Submit clinical notes or measures showing benefit
    • Confirm absence of prohibited concurrent potent immunosuppressant use
    Documentation Required

    Medication trial documentation — required for PA/ST

    Providers must document prior medication trials (specific agents and durations) or documented intolerance as specified for each product when requesting PA or step‑therapy exceptions.

    • Provide dates, agents tried, and reasons for discontinuation or intolerance
    • Follow each product's listed prior‑therapy requirements
    Billing Rule

    Wound care supplies — insulin claim lookback

    For wound care supplies requiring PA, submit claim history showing an insulin product claim within the prior 180 days; absence of that insulin claim may lead to denial.

    • Provide member's pharmacy/medical claim showing insulin within prior 180 days
    Documentation Required

    Prior medication trial documentation — ophthalmic and SGLT2

    For ophthalmic agents (Rhopressa, Rocklatan) and select SGLT2 agents, document prior trial of a generic formulary ophthalmic glaucoma medication or Lumigan, or trial of generic dapagliflozin where specified, prior to approval.

    • Ophthalmic agents: trial of generic ophthalmic glaucoma med or Lumigan required
    • SGLT2s: trial of generic dapagliflozin required except specified Jardiance cardiovascular indication
    Denial Risk

    Tadalafil — nitrate therapy exclusion (denial risk)

    Tadalafil coverage is not provided when patients are receiving nitrate therapy; providers must not request coverage for tadalafil in patients taking nitrates as this will lead to denial.

    • Do not request coverage for tadalafil if patient is on nitrate therapy
    Denial Risk

    Combination biologic/targeted DMARD use — exclusion

    Use of a biologic or targeted DMARD in combination with another biologic/targeted DMARD indicated for the same condition is not permitted and may trigger denial; providers must ensure no overlapping biologic/targeted DMARDs are used.

    • Do not combine two biologic/targeted DMARDs for the same condition
    • Reauthorization requires confirmation the patient is not receiving prohibited combinations
    Denial Risk

    Missing prerequisite therapy — risk of denial

    Requests may be denied if prerequisite therapy/trial and failure requirements are not met (examples: trial of high‑intensity statin for Nexletol/Nexlizet; trial/failure of radioactive iodine for DTC prior to some agents). Providers must document trials or contraindications.

    • Provide documentation of required prior therapies or documented contraindications
    • Absence of documented trials may lead to denial
    Denial Risk

    NASH/MASH — progression to cirrhosis excludes renewal

    Renewal for NASH/MASH therapies (e.g., Rezdiffra) requires that the patient has not progressed to cirrhosis; progression to cirrhosis will preclude renewal.

    • Document no progression to cirrhosis at renewal
    • Provide imaging or blood‑based evidence of improvement/stabilization per renewal criteria
    Denial Risk

    Tetrabenazine — contraindications leading to exclusion

    Use of tetrabenazine will not be provided for patients with hepatic function impairment, those actively suicidal or with untreated/inadequately treated depression, or those taking monoamine oxidase inhibitors or reserpine; providers must confirm absence of these contraindications.

    • Do not initiate/authorize tetrabenazine in hepatic impairment, active suicidality, untreated/inadequately treated depression, or concurrent MAOI/reserpine use
    Prior Authorization

    Verquvo — diagnosis, event, and concomitant therapy requirements

    Verquvo coverage requires diagnosis of chronic heart failure NYHA class II–IV with LVEF <45% plus recent decompensation (hospitalization in prior 6 months or outpatient IV diuretic within prior 3 months) and must be taken in combination with at least two guideline‑directed medical therapy agents unless contraindicated or not tolerated.

    • Document NYHA II–IV and LVEF <45%
    • Provide evidence of recent HF hospitalization (within 6 months) or outpatient IV diuretic (within 3 months)
    • Confirm concurrent use of ≥2 GDMT agents (or document contraindication/intolerance)
    Step Therapy

    Antidepressant step requirement — two generic trials required

    Providers must document trials of at least two listed generic antidepressants for certain antidepressant products (Exxua/Trintellix); absence of those documented trials may cause denial.

    • Provide documentation of trials of ≥2 listed generic antidepressants
    • Lack of documented trials may lead to denial
    Step Therapy

    Antipsychotic step requirement — one generic trial required

    Providers must document trial of at least one listed generic antipsychotic agent for certain antipsychotic products; failure to document such a trial may trigger denial.

    • Document trial of ≥1 listed generic antipsychotic (e.g., aripiprazole, risperidone, quetiapine)
    • Lack of documentation may result in denial
    Denial Risk

    Invega Hafyera — LAI trial durations required (denial risk)

    For Invega Hafyera, coverage requires prior trial of a once‑monthly paliperidone palmitate LAI for ≥4 months OR an every‑three‑month paliperidone palmitate LAI for at least one three‑month cycle; missing documented trial may trigger denial.

    • Document required LAI paliperidone palmitate trial(s) and durations
    • Absence of documented trial may lead to denial
    Denial Risk

    Aristada — trial/intolerance to Abilify Maintena or oral aripiprazole required

    Aristada coverage requires trial or documented intolerance to Abilify Maintena or oral aripiprazole; lack of trial/intolerance documentation may cause denial.

    • Document trial of Abilify Maintena or oral aripiprazole or documented intolerance
    Denial Risk

    Oral risperidone/paliperidone trial — denial risk if missing

    Requests for certain agents may be denied if a trial of oral risperidone or oral paliperidone is not documented (e.g., risperidone ER/paliperidone formulations); providers must submit prior trial documentation.

    • Document trial of oral risperidone or oral paliperidone as required
    • Lack of documentation may result in denial
    Step Therapy

    Febuxostat — allopurinol trial/contraindication required

    Febuxostat requests require documentation of trial or contraindication to allopurinol; absence of such documentation may lead to denial.

    • Provide evidence of allopurinol trial or documented contraindication
    Step Therapy

    Step therapy examples — Ubrelvy and Winrevair

    Providers must follow product‑specific step therapy rules (examples: Ubrelvy requires trial of ≥2 generic triptans unless contraindicated; Winrevair requires trial of generic PDE5 inhibitor and generic endothelin receptor antagonist), and document trials or contraindications when requesting authorization.

    • Ubrelvy: trial of ≥2 generic triptans unless contraindicated or intolerant
    • Winrevair: trial of sildenafil/tadalafil AND bosentan/ambrisentan required
    • Document any contraindications or intolerances claimed
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy Criteria & Requirements

    Reauthorization and Continuation Criteria